What is Wall Street's Target Price for Nabriva Therapeutics PLC - ADR (NBRV) Stock Monday?
Monday, November 28, 2022 02:37 PM | InvestorsObserver Analysts
Mentioned in this article
InvestorsObserver is giving Nabriva Therapeutics PLC - ADR (NBRV) an Analyst Rating Rank of 34, meaning NBRV is ranked higher by analysts than 34% of stocks. The average price target for NBRV is $8 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating NBRV a Buy today. Find out what this means to you and get the rest of the rankings on NBRV!
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Nabriva Therapeutics PLC - ADR Stock Today?
Nabriva Therapeutics PLC - ADR (NBRV) stock is up 1.44% while the S&P 500 is down -1.5% as of 2:37 PM on Monday, Nov 28. NBRV is higher by $0.03 from the previous closing price of $2.17 on volume of 2,375,568 shares. Over the past year the S&P 500 is down -14.81% while NBRV is down -89.59%. NBRV lost -$19.49 per share the over the last 12 months.
Click Here to get the full Stock Report for Nabriva Therapeutics PLC - ADR stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
